7
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Hair disorders associated with post-COVID-19 infection in females: a cross-sectional study

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Coronavirus disease (COVID-19) currently named SARS-CoV-2 is a contagious disease caused by a coronavirus. The virus may infect the hair follicles directly or indirectly through systemic changes in the immune or hormonal systems.

          Aims

          In the current study we aimed to determine the prevalence of hair disorders in females infected with COVID-19.

          Methods

          Data was collected using a questionnaire covering four main domains: personal data, past medical history, COVID-19 history and treatment, and existence of any hair problems and their management. No identifier or sensitive data were collected. Those complaining of hair loss were subjected to complete general and local hair examination using trichoscopy to confirm hair loss.

          Results

          Hair problems were reported in 307 (61.4%) of COVID-19-infected female subjects. A total of 68.1% patients reported that hair loss existed and increased after COVID-19; 29.6% reported their hair problems only post-COVID-19 while 2.3% had hair shedding issues during infection only. The main reported hair problems were telogen effluvium (60.8%), increased gray hair (13.8%), seborrheic dermatitis (5.6%) trichotillomania (3.6%), and alopecia areata (2.2%).

          Conclusion

          In conclusion, we reported prevalence of post-COVID hair fall that was confirmed by trichoscopy and which affected approximately 61.4% of infected females.

          Related collections

          Most cited references18

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          More than 50 long-term effects of COVID-19: a systematic review and meta-analysis

          COVID-19 can involve persistence, sequelae, and other medical complications that last weeks to months after initial recovery. This systematic review and meta-analysis aims to identify studies assessing the long-term effects of COVID-19. LitCOVID and Embase were searched to identify articles with original data published before the 1st of January 2021, with a minimum of 100 patients. For effects reported in two or more studies, meta-analyses using a random-effects model were performed using the MetaXL software to estimate the pooled prevalence with 95% CI. PRISMA guidelines were followed. A total of 18,251 publications were identified, of which 15 met the inclusion criteria. The prevalence of 55 long-term effects was estimated, 21 meta-analyses were performed, and 47,910 patients were included (age 17–87 years). The included studies defined long-COVID as ranging from 14 to 110 days post-viral infection. It was estimated that 80% of the infected patients with SARS-CoV-2 developed one or more long-term symptoms. The five most common symptoms were fatigue (58%), headache (44%), attention disorder (27%), hair loss (25%), and dyspnea (24%). Multi-disciplinary teams are crucial to developing preventive measures, rehabilitation techniques, and clinical management strategies with whole-patient perspectives designed to address long COVID-19 care.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study

            Objectives To describe the prevalence, nature, and risk factors for the main clinical sequelae in COVID-19 survivors who have been discharged from the hospital for more than 3 months. Methods This longitudinal study was based on a telephone follow-up survey of COVID-19 patients hospitalized and discharged from Renmin Hospital of Wuhan University, Wuhan, China before March 1, 2020. Demographic and clinical characteristics and self-reported clinical sequelae of the survivors were described and analysed. A cohort of volunteers who were free of COVID-19 and lived in the urban area of Wuhan during the outbreak were also selected as the comparison group. Results Among 538 survivors (293[54.5%] female), the median age was 52.0 years (IQR 41.0–62.0), and the median time from discharge from hospital to first follow-up was 97.0 days (IQR 95.0–102.0). Clinical sequelae were common, including general symptoms (n=267, 49.6%), respiratory symptoms (n=210, 39%), cardiovascular-related symptoms (n=70, 13%), psychosocial symptoms (n=122, 22.7%) and alopecia (n=154, 28.6%). We found that physical decline/fatigue (P<0.01), post-activity polypnea (P=0.04) and alopecia (P<0.01) were more common in females than in males. Dyspnoea during hospitalization was associated with subsequent physical decline/fatigue, post-activity polypnea and resting heart rate increases, but not specifically with alopecia. A history of asthma during hospitalization was associated with subsequent post-activity polypnea sequela. A history of pulse ≥90 beats per min during hospitalization was associated with resting heart rate increase in convalescence. The duration of viral shedding after COVID-19 onset and hospital length of stay were longer in survivors with physical decline/fatigue or post-activity polypnea than in those without. Conclusion Clinical sequelae during early COVID-19 convalescence were common, and some of these sequelae might be related to gender, age and clinical characteristics during hospitalization.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19)

              In the ongoing coronavirus disease 2019 (COVID-19) pandemic, some unique clinical features have been described [1]. In a report of 44,672 cases from China, a case fatality rate of 2.8% for males versus only 1.7% for females was observed [2]. It has been hypothesized that this may be due a higher prevalence of comorbidities among males, in particular the rate of smoking, which is reported to be 52.1% in men and 2.7% among women in China [3]. However, decreased levels of angiotensin converting enzyme 2 (ACE2), the reported host receptor of the virus responsible of COVID-19 (severe acute respiratory syndrome coronavirus 2; SARS-CoV-2), are observed in smokers [4,5]. In this article, we aimed to investigate the association between active smoking and severity of COVID-19 illness. An electronic search was conducted in Medline (PubMed interface), Scopus and Web of Science, using the keywords “smoking” OR “cigarette” AND “coronavirus 2019” OR “COVID-19” OR “2019-nCoV” OR “SARS-CoV-2”, between 2019 and present time (i.e., March 9, 2020), without language restriction. The title, abstract and full text of all documents captured with these search criteria were scrutinized, and those reporting the rate of active smokers in COVID-19 patients with clinically validated definition of severe disease were included in this meta-analysis. The reference list of the identified studies was also analyzed (forward and backward citation tracking) for detecting other potentially eligible articles. A meta-analysis was then performed, with estimation of the odds ratio (OR) and its 95% confidence interval (95% CI) in patients with or without severe forms of COVID-19. The statistical analysis was carried out using MetaXL, software Version 5.3 (EpiGear International Pty Ltd., Sunrise Beach, Australia). The study was carried out in accordance with the declaration of Helsinki and with the term of local legislation. Overall, 27 documents could be initially identified based on our search criteria and from the reference lists, 22 of which were excluded after title, abstract or full text reading, since they were review articles (n=4), commentaries or other editorial materials (n=2), they did not deal with COVID-19 disease (n=11), or did not provided the rate of active smokers in patients with or without severe disease (n=5). Therefore, 5 studies could finally be included in our meta-analysis, totaling 1399 COVID-19 patients, 288 of whom (20.6%) with severe disease [6], [7], [8], [9], [10]. The essential characteristics of the five included studies are shown in Table 1 , whilst the individual and pooled OR of smoking for predicting severe COVID-19 is shown in Fig. 1 . Overall, in only one study [8] active smoking was found to be a significant predictor of COVID-19 severity, whilst in the other four studies the association was not statistically significant. Despite a trend towards higher risk was appreciable, no significant association could neither be found between active smoking and severity of COVID-19 when data of individual studies were pooled (OR, 1.69; 95% CI, 0.41–6.92; p=0.254). No significant association could also be found when the large study by Guan et al. (89.5% of all samples size) [6] was excluded from statistical analysis (OR, 4.35; 95% 0.86–21.86; p=0.129; I2 , 29%, p=0.24). Table 1 Characteristics of the studies included. Table 1 Authors Setting Sample size Outcome Severe patients Non-severe patients n (%) Age (yrs)* Women (%) n (%) Age (yrs)* Women (%) Guan W et al., 2020 China 1085 Admission to ICU, mechanical ventilation, death. 172 (16%) 52 (40–65) 42% 913 (84%) 45 (34–57) 42% Huang C et al., 2020 China 44 ICU Care 13 (30%) 49 (41–61) 15% 31 (70%) 49 (41–58) 32% Liu W et al., 2020 China 78 Admission to ICU, mechanical ventilation, death. 11 (14%) 66 (51–70) 36% 67 (86%) 37 (32–41) 52% Yang X et al., 2020 China 50 Death 32 (64%) 65 (45–87) 34% 18 (36%) 52 (26–77) 30% Zhang JJ et al., 2020 China 142 Respiratory distress/insufficiency 60 (42%) 64 (25–87) 43% 82 (58%) 52 (26–78) 54% ⁎ Median and interquartile range. Fig. 1 Odds ratio (OR) and 95% confidence interval (95% CI) of active smoking between coronavirus disease 2019 (COVID-19) patients with or without severe disease. . Fig 1 In conclusion, the results of this preliminary meta-analysis based on Chinese patients suggest that active smoking does not apparently seem to be signicantly associated with enhanced risk of progressing towards severe disease in COVID-19. Declaration of Competing Interest None
                Bookmark

                Author and article information

                Contributors
                Egydoc77@yahoo.com
                Journal
                Ir J Med Sci
                Ir J Med Sci
                Irish Journal of Medical Science
                Springer International Publishing (Cham )
                0021-1265
                1863-4362
                14 September 2023
                14 September 2023
                2024
                : 193
                : 2
                : 761-767
                Affiliations
                [1 ]Department of Dermatology, Venereology and Andrology, Damietta Faculty of Medicine, Al-Azhar University, ( https://ror.org/05fnp1145) Damietta, Egypt
                [2 ]Department of Dermatology, Venereology and Andrology, Medical Research and Clinical Studies Institute, National Research Centre, ( https://ror.org/02n85j827) Giza, Egypt
                Author information
                http://orcid.org/0000-0001-7541-5241
                Article
                3509
                10.1007/s11845-023-03509-0
                10961269
                37704885
                d9c558d4-f233-4201-96f8-da23307f00dc
                © The Author(s) 2023

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 8 August 2023
                : 21 August 2023
                Funding
                Funded by: National Research Centre Egypt
                Categories
                Original Article
                Custom metadata
                © Royal Academy of Medicine in Ireland 2024

                Medicine
                alopecia,telogen effluvium,trichoscopy
                Medicine
                alopecia, telogen effluvium, trichoscopy

                Comments

                Comment on this article